Sera Sarsam, Holly Sexton, Jenny Nicolopoulos, Con Dolianitis
{"title":"Guselkumab用于治疗坏疽性脓皮病","authors":"Sera Sarsam, Holly Sexton, Jenny Nicolopoulos, Con Dolianitis","doi":"10.1002/jvc2.547","DOIUrl":null,"url":null,"abstract":"<p>Pyoderma gangrenosum (PG) is a complex disease with limited therapeutic options. Here we report the use of higher dose of guselkumab, a monoclonal antibody targeting interleukin (IL-) 23, in the treatment of PG in a medically complex patient. This case contributes additional evidence supporting the potential effectiveness of guselkumab in the treatment of PG and highlights the necessity for larger studies to confirm these findings.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 1","pages":"240-243"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.547","citationCount":"0","resultStr":"{\"title\":\"Guselkumab for the treatment of pyoderma gangrenosum\",\"authors\":\"Sera Sarsam, Holly Sexton, Jenny Nicolopoulos, Con Dolianitis\",\"doi\":\"10.1002/jvc2.547\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Pyoderma gangrenosum (PG) is a complex disease with limited therapeutic options. Here we report the use of higher dose of guselkumab, a monoclonal antibody targeting interleukin (IL-) 23, in the treatment of PG in a medically complex patient. This case contributes additional evidence supporting the potential effectiveness of guselkumab in the treatment of PG and highlights the necessity for larger studies to confirm these findings.</p>\",\"PeriodicalId\":94325,\"journal\":{\"name\":\"JEADV clinical practice\",\"volume\":\"4 1\",\"pages\":\"240-243\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.547\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JEADV clinical practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jvc2.547\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JEADV clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jvc2.547","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Guselkumab for the treatment of pyoderma gangrenosum
Pyoderma gangrenosum (PG) is a complex disease with limited therapeutic options. Here we report the use of higher dose of guselkumab, a monoclonal antibody targeting interleukin (IL-) 23, in the treatment of PG in a medically complex patient. This case contributes additional evidence supporting the potential effectiveness of guselkumab in the treatment of PG and highlights the necessity for larger studies to confirm these findings.